Evotec Stock Forecast for 2023 - 2025 - 2030
Updated on 04/25/2024
Evotec Stock Forecast and Price Target
The average target price set lately by four experts for Evotec to reach by the end of the year is 25.50€, which would imply a potential upside of approximately 178.38 percent from the previous closing price if it were to be achieved. This prediction is based on a high estimate of 50.00€ and a low estimate of 14.00€. If you're interested in EVT stock, it's important to compare it to other companies in the industry.
178.38% Upside
Evotec Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Evotec's Price has decreased by 100.00%, from 1.36€ to 0.00€. In the next year, analysts believe that Fair Value will reach 9.64€ – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IQV Stock Forecast | IQVIA Holdings | Outperform |
15
|
$233.98 | Buy/Sell | $267.27 | 17.53% |
| IDXX Stock Forecast | IDEXX Laboratories | Outperform |
14
|
$489.24 | Buy/Sell | $583.92 | 22.64% |
| ICLR Stock Forecast | ICON Public | Buy |
16
|
$300.08 | Buy/Sell | $306.07 | 19.97% |
| ARGX Stock Forecast | argenx | Outperform |
4
|
346.20€ | Buy/Sell | 531.81€ | 26.52% |
| GMAB Stock Forecast | Genmab A/S | Outperform |
16
|
kr1.92k | Buy/Sell | kr2.71k | 33.91% |
Evotec Revenue Forecast for 2023 - 2025 - 2030
Evotec's Revenue has seen impressive growth In the last three years, rising from 500.92€M to 781.43€M – a growth of 56.00%. In the next year, analysts believe that Revenue will reach 939.50€M – an increase of 20.23%. For the next seven years, the forecast is for Revenue to grow by 74.74%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SRT3 Stock Forecast | Sartorius | Outperform |
18
|
282.10€ | Buy/Sell | 281.57€ | 18.75% |
| LH Stock Forecast | Laboratory Corp of America Hol... | Outperform |
11
|
$198.35 | Buy/Sell | $241.28 | 21.50% |
| SGSN Stock Forecast | SGS | Hold |
18
|
CHF82.10 | Buy/Sell | CHF86.34 | 9.62% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DGX Stock Forecast | Quest Diagnostics | Outperform |
10
|
$135.42 | Buy/Sell | $141.17 | 7.07% |
| BVI Stock Forecast | Bureau Veritas | Outperform |
18
|
27.32€ | Buy/Sell | 26.96€ | 13.47% |
| MEDP Stock Forecast | Medpace Holdings | Outperform |
14
|
$389.77 | Buy/Sell | $281.20 | 15.45% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ERF Stock Forecast | Eurofins Scientific | Hold |
18
|
57.50€ | Buy/Sell | 0.00€ | 2.61% |
| CRL Stock Forecast | Charles River Laboratories Int... | Outperform |
16
|
$227.81 | Buy/Sell | $229.97 | 21.48% |
| REC Stock Forecast | Recordati Industria Chimica e ... | Hold |
18
|
48.80€ | Buy/Sell | 48.61€ | 5.43% |
Evotec EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Evotec's EBITDA has seen a drop from 88.31€M to 72.09€M – a 18.37% decrease. Analysts predict that Evotec's EBITDA will increase in the upcoming year, reaching 172.18€M. This would represent an increase of 138.84%. Over the next seven years, experts predict that Evotec's EBITDA will grow at a rate of 501.89%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CTLT Stock Forecast | Catalent | Hold |
15
|
$55.80 | Buy/Sell | $49.29 | 13.80% |
| ITRK Stock Forecast | Intertek Group | Outperform |
18
|
£49.48 | Buy/Sell | £44.87 | 6.71% |
| SHL Stock Forecast | Sonic Healthcare | Hold |
18
|
$26.74 | Buy/Sell | $34.12 | 15.93% |
Evotec EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Evotec's EBIT has gone down from 51.01€M to 1000.00€k – a 98.04% drop. In the next year, analysts believe that EBIT will reach 68.46€M – an increase of 6746.00%. For the next seven years, the forecast is forEBIT to grow by 31433.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BANB Stock Forecast | Bachem Holding | Hold |
16
|
CHF79.90 | Buy/Sell | CHF616.00 | 0.13% |
| HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£18.54 | Buy/Sell | £28.11 | 57.55% |
| ABCM Stock Forecast | Abcam | - |
18
|
$23.99 | Buy/Sell | $19.25 | -67.15% |
Evotec EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Evotec's EPS has decreased by 100.00%, from 0.04€ to 0.00€. In the next year, analysts believe that EPS will reach 0.21€ – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ZEAL Stock Forecast | Zealand Pharma A/S | Outperform |
8
|
kr599.00 | Buy/Sell | kr357.00 | 36.06% |
| TECN Stock Forecast | Tecan Group | Outperform |
18
|
CHF327.20 | Buy/Sell | CHF406.33 | 22.25% |
| ORNBV Stock Forecast | Orion Oyj | Hold |
14
|
35.39€ | Buy/Sell | 42.52€ | 18.68% |
.jpg)